Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) made headlines earlier in the week when it revealed that the US Food and Drug Administration had granted its lead drug candidate CardiolRx orphan drug designation, indicating potential efficacy in treating recurrent pericarditis. The designation provides benefits such as marketing exclusivity and fee reduction, and the company's share prices have surged as a result. Cardiol's focus on addressing the symptoms of recurrent pericarditis, including chest pain and red ...

About this content About Leo Grieco Leo joins us with a degree in Media Production from Bournemouth University. His work includes reporting for the UK editorial team and video editing for the broadcast team. He comes with an expertise in video editing and producing. Leo’s specialities include hospitality and leisure, support services, tech and video games. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and fi ...

Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars) Unaudited Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Cash Flows (Expressed in Canadian Dollars) Unaudited Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Changes in Equity (Expressed in Canadian Dollars) Unaudited - 5 - CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPT ...

Exhibit 99.1 Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars) Unaudited CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED JUNE 30, 2023 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) | | Three Months | | Three Months | | Six Months | | Six Months | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Ended | | Ended | | Ended | | Ended | | | | June 30, | | June 30, | ...

Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and ef icacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizations 2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Year-End 2022 Update on Operations . Initiated p ...

In December 2020, Cardiol announced the appointment of CRO Worldwide Clinical Trials ("Worldwide") for its Phase II/III trial in high-risk patients hospitalized with COVID-19. In February 2021, the Corporation received proceeds of $7,879,820 on the exercise of 2,424,560 warrants with an exercise price of $3.25, and $503,068 on the exercise of 201,227 warrants with an exercise price of $2.50. In addition, there were a total of 916,666 stock option exercises, resulting in cumulative proceeds of $2,604,648. Dr ...

Exhibit 99.1 CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2022 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) Unaudited | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------|-------|-------|--------------------------|-------|-----------------------------| | ASSETS | | | As at Marc ...

CardiolRx Pharmaceutical CBD - CardiolRx计划于2019年上市，目标是纯度最高、最安全的CBD疗法[8, 10, 60] - 2018年的一项消费者调查显示，76%的消费者在选择CBD来源时最看重质量和安全[16] - 医药CBD市场预计将达到12亿美元[10] - 预计加拿大医疗市场将加速增长至超过23.1亿加元[15] Acute Myocarditis Orphan Drug Program - 急性心肌炎符合美国和欧洲孤儿药资格[29] - 美国患者估计患病人数为73000人[33] Heart Failure Therapies - 美国和加拿大有超过600万成年人患有心力衰竭[41] - 心力衰竭是导致住院的主要原因，在美国每年的医疗费用超过300亿美元[41] - TecSalud承诺向Cardiol投资300万美元，以支持纳米疗法研究[57] Capital Structure - 公司内部人士和员工持股比例为33%[75] - 制药合作伙伴和研究合作者（不包括内部人士）的持股比例为8%[75] - 截至2019年6月30日，公司拥有现金和现金等价物1250万加元[75] - 截至2019年6月30日，公司拥有1880万加元流动资金，其中包括630万加元的库存和预付库存[75]

BARDIOL | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The Next Generation of CBD | | | | | | | | | | | | | | | | | | | | | | | | Disclaimer In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of Cardiol or any other entity contained in this present ...